Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Video interview with Sara Hurvitz
4. Ramucirumab plus erlotinib improves progression-free survival in EGFR-positive lung cancer
This newsletter presents you the following key sessions:
1. Video interview with Sara Hurvitz
4. Ramucirumab plus erlotinib improves progression-free survival in EGFR-positive lung cancer
Medical writer
Medical writer